Inonotsuoxide B suppresses hepatic stellate cell activation and proliferation via the PI3K/AKT and ERK1/2 pathway.

Hepatic stellate cells (HSCs) serve a pivotal role in the formation and degradation of the extracellular matrix during liver fibrosis. Inonotsuoxide B is a tetracyclic triterpenoid that can be extracted from and has been previously reported to inhibit the growth of liver and gastric cancer cells. However, its effect on liver fibrosis remain poorly understood. Therefore, in the present study, the potential antiproliferative effects of inonotsuoxide B on HSCs was investigated. Initially, cells were divided into the following five groups: Control; platelet-derived growth factor (PDGF)-BB (10 ng/ml); and PDGF-BB + inonotsuoxide B (5, 10 and 20 µg/ml) groups. Inonotsuoxide B treatment (5, 10 and 20 µg/ml) was revealed to reverse PDGF-BB-induced HSC proliferation. Furthermore, the protein expression of α-smooth-muscle actin (α-SMA) and type I collagen was significantly decreased in the inonotsuoxide B (10 and 20 µg/ml) groups compared with the PDGF-BB group. Inonotsuoxide B (5, 10 and 20 µg/ml) was also revealed to suppress PDGF-BB-induced α-SMA mRNA expression and activation of the PI3K/AKT and ERK signaling pathways in HSCs. These findings suggest that inonotsuoxide B suppresses the proliferation and activation of HSCs by inhibiting the PI3K/AKT and ERK1/2 signaling pathways.